198 related articles for article (PubMed ID: 31373466)
1. [The Fabry nephropathy: new insight in diagnosis, monitoring and treatment].
Mignani R
G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373466
[TBL] [Abstract][Full Text] [Related]
2. Hot topics in Fabry disease.
Cairns T; Müntze J; Gernert J; Spingler L; Nordbeck P; Wanner C
Postgrad Med J; 2018 Dec; 94(1118):709-713. PubMed ID: 30559317
[TBL] [Abstract][Full Text] [Related]
3. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
[TBL] [Abstract][Full Text] [Related]
4. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
[No Abstract] [Full Text] [Related]
5. Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta.
Ito S; Ogura M; Kamei K; Matsuoka K; Warnock DG
Pediatr Nephrol; 2016 Aug; 31(8):1369-73. PubMed ID: 27129690
[TBL] [Abstract][Full Text] [Related]
6. Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy.
Torra R; Algaba F; Ars E; Santin S; Fernández-Llama P; Ballarin J
Clin Nephrol; 2008 Jun; 69(6):445-9. PubMed ID: 18538121
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
[TBL] [Abstract][Full Text] [Related]
8. Renal complications of Fabry disease.
Basic-Jukic N; Kes P; Coric M; Basic-Kes V
Curr Pharm Des; 2013; 19(33):6046-50. PubMed ID: 23448456
[TBL] [Abstract][Full Text] [Related]
9. Fabry Disease Therapy: State-of-the-Art and Current Challenges.
Azevedo O; Gago MF; Miltenberger-Miltenyi G; Sousa N; Cunha D
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379210
[TBL] [Abstract][Full Text] [Related]
10. Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.
Whitfield PD; Calvin J; Hogg S; O'Driscoll E; Halsall D; Burling K; Maguire G; Wright N; Cox TM; Meikle PJ; Deegan PB
J Inherit Metab Dis; 2005; 28(1):21-33. PubMed ID: 15702403
[TBL] [Abstract][Full Text] [Related]
11. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
12. Migalastat: A Review in Fabry Disease.
McCafferty EH; Scott LJ
Drugs; 2019 Apr; 79(5):543-554. PubMed ID: 30875019
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
14. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
[TBL] [Abstract][Full Text] [Related]
15. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
[TBL] [Abstract][Full Text] [Related]
16. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
Waldek S; Feriozzi S
BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
19. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts.
Spada M; Baron R; Elliott PM; Falissard B; Hilz MJ; Monserrat L; Tøndel C; Tylki-Szymańska A; Wanner C; Germain DP
Mol Genet Metab; 2019 Mar; 126(3):212-223. PubMed ID: 29785937
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
Lenders M; Brand E
Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
